PUBLISHER: Grand View Research | PRODUCT CODE: 1609958
PUBLISHER: Grand View Research | PRODUCT CODE: 1609958
The global saliva collection and diagnostics market size is estimated to reach USD 1,100.2 million by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Owing to the increasing prevalence of communicable and non-communicable diseases along with the increasing preference for non-invasive methods for disease diagnosis. Moreover, the growing need to diagnose COVID-19-infected symptomatic and asymptomatic patients have created significant opportunities for the market. In August 2022, a research study published in PLOS ONE stated that oral fluid samples could be used for various diagnostic assays, such as COVID-19, due to its storage and ease of sample collection. Moreover, researchers have also stated that even if the salivary samples were stored for more than 28 days, it would remain reliable and useful.
Furthermore, the global burden of cancer and related deaths rose in 2020, majorly because of the increasing aging population and socioeconomic development. In April 2020, an article published in the American Society of clinical oncology stated that more than 50% of cancers globally are diagnosed in people aged 65 and older. Therefore, the saliva-based test is considered to be the best non-invasive procedure to detect cancer. In August 2022, OrisDX announced of developing a saliva-based non-invasive molecular test to diagnose and detect oral cancer at an early stage which would help in improving patient outcomes.
There has been significant growth in the adoption of saliva samples for both clinical and research applications as it offers non-invasive sampling, easy, simple collection, and higher patient compliance, among others. Several advancements and developments are happening in saliva specimens which would advance the proteomics field. For instance, in September 2022, an article published in India Today stated that researchers from IIT Roorkee identified salivary proteins which could help in predicting metastatic triple-negative breast cancer.
Key players operating in the market are taking several initiatives such as entering into strategic alliances and launching new products which are contributing to the overall growth. For instance, in January 2021, OraSure Technologies, Inc. announced that its saliva collection device, OMNIgene*ORAL, has been selected by Chronomics Limited for the SARS CoV-2 PCR test. Similarly, in August 2020, Fluidigm Corporation announced receiving FDA authorization for its saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR assay. This test would help to detect the presence of coronavirus in the sample.